72.89
price down icon0.75%   -0.55
after-market After Hours: 72.23 -0.66 -0.91%
loading
Moderna Inc stock is traded at $72.89, with a volume of 3.37M. It is down -0.75% in the last 24 hours and down -11.43% over the past month. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$73.44
Open:
$73.44
24h Volume:
3.37M
Relative Volume:
0.91
Market Cap:
$28.02B
Revenue:
$4.99B
Net Income/Loss:
$-5.87B
P/E Ratio:
-7.7957
EPS:
-9.35
Net Cash Flow:
$-3.98B
1W Performance:
-5.83%
1M Performance:
-11.43%
6M Performance:
-25.70%
1Y Performance:
-32.66%
1-Day Range:
Value
$71.65
$73.60
1-Week Range:
Value
$71.51
$77.75
52-Week Range:
Value
$62.55
$170.47

Moderna Inc Stock (MRNA) Company Profile

Name
Name
Moderna Inc
Name
Phone
(617) 714-6500
Name
Address
325 BINNEY STREET, CAMBRIDGE
Name
Employee
5,600
Name
Twitter
@moderna_tx
Name
Next Earnings Date
2024-08-01
Name
Latest SEC Filings
Name
MRNA's Discussions on Twitter

Moderna Inc Stock (MRNA) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-02-24 Upgrade Oppenheimer Perform → Outperform
Nov-29-23 Initiated Canaccord Genuity Hold
Nov-03-23 Upgrade HSBC Securities Reduce → Hold
Nov-02-23 Downgrade Deutsche Bank Hold → Sell
Aug-04-23 Downgrade TD Cowen Outperform → Market Perform
Aug-03-23 Downgrade Deutsche Bank Buy → Hold
Jul-24-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Reduce
Jun-26-23 Upgrade UBS Neutral → Buy
Apr-26-23 Initiated Guggenheim Neutral
Mar-13-23 Upgrade TD Cowen Market Perform → Outperform
Mar-02-23 Initiated RBC Capital Mkts Outperform
Feb-24-23 Downgrade SVB Securities Market Perform → Underperform
Dec-19-22 Upgrade Jefferies Hold → Buy
Dec-14-22 Downgrade Chardan Capital Markets Buy → Neutral
Oct-21-22 Upgrade SVB Leerink Underperform → Mkt Perform
Sep-08-22 Upgrade Deutsche Bank Hold → Buy
Feb-01-22 Upgrade Redburn Sell → Neutral
Jan-26-22 Upgrade Deutsche Bank Sell → Hold
Jan-21-22 Upgrade BofA Securities Underperform → Neutral
Jan-21-22 Initiated UBS Neutral
Dec-07-21 Initiated Cowen Market Perform
Nov-09-21 Initiated Wolfe Research Outperform
Oct-22-21 Initiated Deutsche Bank Sell
Oct-15-21 Upgrade Piper Sandler Neutral → Overweight
Aug-06-21 Downgrade Oppenheimer Outperform → Perform
Aug-06-21 Downgrade Piper Sandler Overweight → Neutral
Jul-15-21 Reiterated Jefferies Hold
Feb-01-21 Downgrade BofA Securities Neutral → Underperform
Dec-16-20 Downgrade Jefferies Buy → Hold
Dec-16-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-20 Downgrade Needham Buy → Hold
Nov-23-20 Initiated Wells Fargo Equal Weight
Nov-17-20 Downgrade BMO Capital Markets Outperform → Market Perform
Sep-08-20 Downgrade SVB Leerink Mkt Perform → Underperform
Jul-23-20 Initiated SVB Leerink Mkt Perform
Jul-20-20 Downgrade JP Morgan Overweight → Neutral
Jul-13-20 Initiated Jefferies Buy
Jun-30-20 Initiated Argus Buy
Jun-08-20 Initiated Barclays Overweight
Apr-30-20 Initiated BMO Capital Markets Outperform
Mar-05-20 Downgrade BofA/Merrill Buy → Neutral
Dec-03-19 Resumed BofA/Merrill Buy
Oct-25-19 Initiated ROTH Capital Buy
Apr-05-19 Initiated Chardan Capital Markets Buy
View All

Moderna Inc Stock (MRNA) Latest News

pulisher
Sep 08, 2024

Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio? - Benzinga

Sep 08, 2024
pulisher
Sep 08, 2024

MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit - Morningstar

Sep 08, 2024
pulisher
Sep 07, 2024

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - Markets Insider

Sep 07, 2024
pulisher
Sep 07, 2024

Is It Time to Buy August's Worst-Performing Nasdaq Stocks? - The Motley Fool

Sep 07, 2024
pulisher
Sep 06, 2024

Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch

Sep 06, 2024
pulisher
Sep 06, 2024

Moderna's Investigational Mpox Vaccine More Effective Than Current Approved Shot, Animal Study Shows - Benzinga

Sep 06, 2024
pulisher
Sep 06, 2024

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - MSN

Sep 06, 2024
pulisher
Sep 06, 2024

Pandemic darling Moderna needs a reality check | Company Business News - Mint

Sep 06, 2024
pulisher
Sep 06, 2024

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - Yahoo Finance

Sep 06, 2024
pulisher
Sep 06, 2024

MRNA Gets Positive CHMP Opinion for Updated COVID-19 Jab - Zacks Investment Research

Sep 06, 2024
pulisher
Sep 06, 2024

Pandemic Darling Moderna Needs a Reality Check - The Wall Street Journal

Sep 06, 2024
pulisher
Sep 06, 2024

MRNA LAWSUIT ALERT: Levi & Korsinsky Notifies Moderna, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - PR Newswire

Sep 06, 2024
pulisher
Sep 05, 2024

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - PR Newswire

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna's updated COVID vaccine nears EU approval - Investing.com

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna mpox mRNA vaccine shows early promise in monkey study - Pharmaceutical Technology

Sep 05, 2024
pulisher
Sep 05, 2024

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. - GlobeNewswire

Sep 05, 2024
pulisher
Sep 05, 2024

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Moderna, Inc. Investors to Secure Counsel Before - The Bakersfield Californian

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna mpox mRNA vaccine shows early promise in monkey study - Clinical Trials Arena

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna mpox mRNA vaccine shows early promise in monkey study - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

Bavarian Nordic stock slides on Moderna mpox vaccine study (NASDAQ:MRNA) - Seeking Alpha

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna: CHMP gives green light to new Covid vaccine - Marketscreener.com

Sep 05, 2024
pulisher
Sep 05, 2024

Could This Be the Catalyst Novavax Needs to Get Its Stock Rallying Again? - The Motley Fool

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna updated COVID shot endorsed in EU (NASDAQ:MRNA) - Seeking Alpha

Sep 05, 2024
pulisher
Sep 05, 2024

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 - Yahoo Finance

Sep 05, 2024
pulisher
Sep 05, 2024

Moderna, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before October 8, 2024 to Discuss Your RightsMRNA - PR Newswire

Sep 05, 2024
pulisher
Sep 05, 2024

Column: Some people can wait to get the new COVID shot - Yakima Herald-Republic

Sep 05, 2024
pulisher
Sep 05, 2024

EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.1 - Via Ritzau

Sep 05, 2024
pulisher
Sep 04, 2024

Moderna, Inc. ShareholdersRobbins LLP Reminds MRNA - GlobeNewswire

Sep 04, 2024
pulisher
Sep 04, 2024

Some people can wait to get the new COVID shot - 코리아타임스

Sep 04, 2024
pulisher
Sep 04, 2024

UK, Taiwan Approve Moderna's Updated COVID-19 Shot - MSN

Sep 04, 2024
pulisher
Sep 04, 2024

Stephen Hoge Sells 318 Shares of Moderna, Inc. (NASDAQ:MRNA) Stock - MarketBeat

Sep 04, 2024
pulisher
Sep 04, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Moderna - Stockhouse Publishing

Sep 04, 2024
pulisher
Sep 04, 2024

Mpox Protection: Moderna’s New mRNA Vaccine May Beat Today’s MVA Shot - Genetic Engineering & Biotechnology News

Sep 04, 2024
pulisher
Sep 04, 2024

MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna's mRNA-based mpox vaccine shows promise in trials - UPI News

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna MRNA Mpox Vaccine Shows Promise In Animal Study - Barron's

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna’s experimental mpox vaccine reduces severity of disease, study finds - MarketWatch

Sep 04, 2024
pulisher
Sep 04, 2024

COVID shots are no longer free for the uninsured - WWNY

Sep 04, 2024
pulisher
Sep 04, 2024

Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031 - GlobeNewswire

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna Receives MHRA Authorisation for Updated Covid-19 Vaccine - European Pharmaceutical Manufacturer

Sep 04, 2024
pulisher
Sep 04, 2024

MRNA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Moderna, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna’s COVID-19 mRNA vaccine targeting SARS-COV-2 Variant JN.1 receives approval in Taiwan - BSA bureau

Sep 04, 2024
pulisher
Sep 04, 2024

Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat

Sep 04, 2024
pulisher
Sep 03, 2024

Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Sep 03, 2024
pulisher
Sep 03, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRNA - PR Newswire

Sep 03, 2024
pulisher
Sep 03, 2024

What's Going On With Moderna Stock On Tuesday?Moderna (NASDAQ:MRNA) - Benzinga

Sep 03, 2024
pulisher
Sep 03, 2024

Moderna: green light for new Covid vaccine in the UK - Marketscreener.com

Sep 03, 2024
pulisher
Sep 03, 2024

Moderna, Amgen, Other Pharma Stocks Have Clinical Trials That Could Send Them Soaring - Barron's

Sep 03, 2024
pulisher
Sep 03, 2024

Moderna’s updated COVID-19 vaccine wins U.K. approval (NASDAQ:MRNA) - Seeking Alpha

Sep 03, 2024

Moderna Inc Stock (MRNA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$246.78
price down icon 1.87%
$542.00
price down icon 1.18%
$89.94
price down icon 0.23%
$191.32
price down icon 0.14%
$27.52
price down icon 0.61%
Cap:     |  Volume (24h):